• by bcarlson@marketresearch.com
  • January 29 2014


The Med Device Tax: From the Entrepreneur Point of View

The Med Device Tax: From the Entrepreneur Point of View

The Affordable Care Act included a now well-known tax on the medical devices industry. The tax was 2.3% on sales of FDA approved medical devices. A perspective on the impact of this tax and other changes on the device industry is provided by our analyst Mary Ann Crandall, who is also the owner of Spectron IR, a company that offers Thermal imaging systems (www.spectronir.com). Spectron IR is a very small company and has been hit with extra fees and taxes that have been imposed on the medical devi...


Hospital & Independent Lab Testing in the Clinical Testing Market

Hospital & Independent Lab Testing in the Clinical Testing Market

The interplay or competitive balance between independent laboratories and hospital labs in the United States merits attention in the coming years as the future of clinical testing will be overwhelmingly shaped in the two segments. After seeing business contract by nearly 5% over the past five years , independent labs are projected by Kalorama Information to realize new growth in an altered U.S. healthcare landscape. The Affordable Care Act (ACA) will create opportunities to expand for all labs, ...


Beacons in Southeast Asia: IVD Market Opportunities in Singapore and Malaysia

Beacons in Southeast Asia: IVD Market Opportunities in Singapore and Malaysia

Behind China, the countries of Southeast Asia represent IVD market similarly bolstered through economic growth and strong state-driven efforts to improve national healthcare systems. Immediate inroads into the Southeast Asian IVD market can be forged through Singapore and Malaysia, two countries already favored through their position at the nexus of Asian trade. Representing a combined IVD market of over $200 million, Singapore and Malaysia are modest only in comparison to Asia’s leading markets...

  • by bcarlson@marketresearch.com
  • January 21 2014


Clinical Lab Services Grow, Despite Cuts

Clinical Lab Services Grow, Despite Cuts

Some of the most common tests in routine medical practice saw Medicare reimubursement cuts between 2009 and 2013, as shown in the accompanying table. Tests for Aluminum, Iron, Vitamin B12, BUN are among those that averaged a 5.8% decrease. Yet the industry found a way to grow a little bit. Just a little bit. The market, according to our estimate in a recent report , grew just over one percent in the past five years.

We estimated at the market at $99.1 billion for 2013, up 1.3% Our report notes...


Next Generation Sequencing (NGS) Brings New World to Clinical Research

Next Generation Sequencing (NGS) Brings New World to Clinical Research

The ambition of BGI, previously Beijing Genomics Institute, was on display in its recent profile. The increasingly diversified researcher has already accomplished so-called “mass-production” cloning with 500 cloned pigs a year. A team of BGI technicians is able to complete in vitro fusion of donor DNA into unfertilized eggs under a microscope. The cloned pigs will be used to conduct trials for new human medicines.

Next door at the same facility, next-generation sequencers are laying the founda...

  • by bcarlson@marketresearch.com
  • January 13 2014


IVD Companies Must Comply With Sunshine Act

IVD Companies Must Comply With Sunshine Act

Marketers for IVD products will have to disclose payments made to pathology labs, whether they come in the form of discounts, travel or small trinkets. Congress passed the Physician Sunshine Payment Act in 2010 as part of the Affordable Care Act (ACA) to thwart the influence of financial perks on healthcare costs. Pathologists and other lab workers are included in the law’s scope. The new rules are the same rules as followed pharma companies when it comes to the rmarketing according to a story i...


Hematology Industry Focus: Beckman Coulter

Hematology Industry Focus: Beckman Coulter

Playing second fiddle to Sysmex on the global stage in hematology, Beckman Coulter remains the U.S. market leader and a major innovator in hematology workstation solutions for increasingly cost-pressured clinical lab clients.

As part of the recently published The World Market for Hematology , Kalorama Information investigated Beckman Coulter’s position in the IVD segment and the steps the company is taking to shape its future role.

By any indicator, Beckman Coulter lost its leading global ma...

  • by bcarlson@marketresearch.com
  • January 8 2014


99 Billion Dollars In Clinical Lab Services Sold

99 Billion Dollars In Clinical Lab Services Sold

The interest in diagnostics as an industry should not be surprising; It is estimated that approximately 80% of physician’s diagnoses are a result of a lab test. Though some physicians can conduct tests in an office lab, a fair number of these tests are sent to clinical lab service providers. There is constant pressure to reduce healthcare spending, and that in turn is shifting healthcare utilization in favor of the laboratory. All of these are drivers to the 99.1 billion-dollar clinical lab serv...

  • by bcarlson@marketresearch.com
  • January 3 2014


Kalorama Predicts MedTech Trends: MDDI Magazine

Kalorama Predicts MedTech Trends: MDDI Magazine

As this MD+DI article demonstrates, the price of new taxes and costs to device makers may be this - less R&D spending by medical device cos.. And this means less innovation. In the interview, we noted that although the full picture for 2013 remains to be seen, there was less growth in R&D spending-not a decline, but less growth-in 2012. We expect 2013 to end up painting a similar picture.

"How does medtech grow long-term when there could be less money within internal budgets and from investor ...